Shield Therapeutics plc (LON:STX – Get Free Report) passed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of GBX 3.06 ($0.04) and traded as low as GBX 3 ($0.04). Shield Therapeutics shares last traded at GBX 3.10 ($0.04), with a volume of 893,979 shares changing hands.
Shield Therapeutics Stock Up 1.6 %
The company has a market cap of £30.59 million, a PE ratio of -0.80 and a beta of 1.42. The company has a debt-to-equity ratio of 3,691.50, a quick ratio of 2.16 and a current ratio of 1.05. The company has a fifty day moving average of GBX 3.06 and a two-hundred day moving average of GBX 3.39.
Insider Activity at Shield Therapeutics
In other Shield Therapeutics news, insider Anders Lundstrom bought 575,000 shares of Shield Therapeutics stock in a transaction that occurred on Thursday, February 13th. The stock was purchased at an average price of GBX 4 ($0.05) per share, with a total value of £23,000 ($29,792.75). 62.16% of the stock is owned by insiders.
About Shield Therapeutics
Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S.
Further Reading
- Five stocks we like better than Shield Therapeutics
- Comparing and Trading High PE Ratio Stocks
- 3 Undervalued Stocks You Can Buy at a Discount Now
- How to Plot Fibonacci Price Inflection Levels
- AMD Stock: Can the PC Refresh Cycle Spark a Rally?
- Most Volatile Stocks, What Investors Need to Know
- Micron Stock Spikes 7%—3 Key Catalysts Behind the Move
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
